http://beatthestreetgroup.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AXLX on radar today!
$AXLX on radar today!
$AXLX on radar today!
Mobsters Friday Hit List is $AXLX
AXLX - Axiologix, Inc.
Company Overview
Website - http://www.axiologix.net
Axiologix is an International Technology and Services Organization focused on delivering Cloud-based Products and Services.
Axiologix is creating a nationwide Service Provider of Voice, Data and Cloud services to small and medium size businesses primarily in the United States, and to other operators globally by acquiring strategic technology assets and existing turnkey VoIP and independent operators. This approach avoids the higher risk and more costly model of relying on exclusively organic growth.
On January 17, 2012 Axiologix acquired substantially all of the assets and liabilities of VOIP ACQ, Inc. that has a number of agreements to make further acquisitions in the VoIP and Cloud Services markets.
On March 5, 2012 Axiologix, through a wholly owned subsidiary in Ireland, Axiologix Limited, acquired substantially all of the assets of Prime Carrier Limited, a Cloud services company serving the international telecoms marketplace that continues to trade under the business name Prime Carrier.
Axiologix is headquartered in Sarasota, FL with International operations in Dublin, Ireland.
Subsidiaries
http://www.axiologix.net/subsidiariesall.html
Axiocomm is a Technology and Services Organization focused on delivering Hosted PBX/VoIP and other cloud based services.
Axiocomm is a wholly owned subsidiary to offer IP voice, data and Cloud services directly to small and medium sized businesses throughout the United States.
To this end AxioComm is partnering with leading technology and service providers to allow us to offer exciting new and competitive services to customers across the United States. AxioComm services are currently being sold via master sales agents that bring a large network of sales resources across the nation.
For further information of Axiocomm's solutions please visit - http://www.axiocomm.net
International Wholesale Carrier Rate & Route Optimization Software
On March 5, 2012 Axiologix completed the acquisition of the assets, business operations and customer contracts of Prime Carrier Ltd., through a wholly owned subsidiary Axiologix Ltd., based in Dublin, Ireland.
Following this acquisition Axiologix Ltd. will continue the business under the registered business name "Prime Carrier".
Prime Carrier is the proven leader in ‘On Demand’ solution to support inter-carrier trading of International Voice traffic. The MOST solution offers an easy-to-use Cloud-based software that can reduce a Telecommunication Carrier's costs by ensuring that the best rates are used in their Traffic Routing.
For further information of Prime Carrier's solutions please visit - http://www.primecarrier.com
Prime Carrier is a registered business name of Axiologix Ltd, Company Number: 443993
Registered Offices: Lis Cara Business Centre, 51-52 Fitzwilliam Square West, Dublin 2, Ireland
Axiologix, Inc. is publicly traded on the OTC Market under the symbol, “AXLX”, and within the OTC-PINK Current Information market tier. As such, Business, Operational, and Financial information on AXLX is available to public view.
Visit: http://www.otcmarkets.com/stock/AXLX/company-info to see complete details.
Axiologix, Inc. is Active on the Nevada Secretary of State site:
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=GxMpei%252bcW5URsoF2m9EV%252fw%253d%253d&nt7=0
A/S: 3 Billion
O/S: 1.2 Billion
FLOAT: 360 Million
(Please note the share structure posted is what we have gathered but can change on a daily basis. Contact the Company or Transfer Agent to get the most current information.)
Their latest 10-Q Quarterly Report:
Filed on 2/20/13 ~ For the period ending 11/30/12
http://www.otcmarkets.com/financialReportViewer?symbol=AXLX&id=99608
Incorporated In: Nevada in 2011
Transfer Agent:
American Stock Transfer & Trust Company
Operations Center
6201 15th Avenue
Brooklyn, NY 11219
Phone: 718-921-8200
News Disclaimer - The following Press Releases have not been investigated by Penny Stock Mobsters, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the links for the following press releases may be from a familiar and reputable company, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. Penny Stock Mobsters will not be held responsible for any news release including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.
PR Newswire - (February 26)
Axiologix Enters Into $800,000 Equity Transaction With Institutional Investor Ironridge Technology Co. - Underpinning Growth And Acquisition Strategy
http://finance.yahoo.com/news/axiologix-enters-800-000-equity-140200370.html
PR Newswire - (February 20)
Axiologix To Acquire Leading Provider Of IP Voice, Data And Managed Services With Revenues Exceeding $6M Per Year
http://finance.yahoo.com/news/axiologix-acquire-leading-provider-ip-123000457.html
PR Newswire - (February 11)
Axiologix subsidiary axiocomm launches new website and online ordering capability for nationwide business phone services
http://finance.yahoo.com/news/axiologix-subsidiary-axiocomm-launches-website-131700080.html
PR Newswire - (January 14)
Axiologix Subsidiary Announces Partnership To Offer IP Voice, Data And Cloud Services Via Nationwide Agent Channel
http://finance.yahoo.com/news/axiologix-subsidiary-announces-partnership-offer-183100429.html
Contact Us:
US Headquarters
Axiologix, Ltd.
1990 Main Street, Suite 750,
Sarasota, FL 34236
Fax: +1 (908) 781 1489
Telephone: +1 (908) 719 8920
International Headquarters
Axiologix, Ltd.
Lis Cara Business Centre
51-52 Fitzwilliam Square West
Dublin 2
Ireland
Fax: +353 (0)1 6650480
Telephone: +353 (0)1 665 0448
This Alert Brought to you by Wall Street Mobsters
Contact Us - admin@pennystockmobsters.com
Newsletter Sign Up - http://trumpia.com/onlineSignup/PSMobsters/Family
Penny Stocks are very volatile and with investing in any security there is always risk.
Always Educate yourself and do your own Due Diligence before investing in ANY Security.
Sources: http://www.bloomberg.com - http://www.finance.yahoo.com - http://www.businessweek.com - http://www.otcmarkets.com/marketActivity/current-otc-market
(these are only sources and not always up to date)
If you are new to trading penny stocks we strongly advise you to spend some time trading virtual money. They say that “You never really become a real trader until you wipeout your portfolio.” We say take that wipeout while not losing your real money.
Here are a few sites where you can easily set up a virtual account:
First check your broker, some have them already like TD Ameritrade/Think or Swim
https://www.tdameritrade.com/tradingtools/compareplatforms.html
Howthemarketworks.com
http://www.howthemarketworks.com
Wallstreetsurvivors.com
http://www.wallstreetsurvivor.com
Mobsters Friday Hit List is $AXLX
AXLX - Axiologix, Inc.
Company Overview
Website - http://www.axiologix.net
Axiologix is an International Technology and Services Organization focused on delivering Cloud-based Products and Services.
Axiologix is creating a nationwide Service Provider of Voice, Data and Cloud services to small and medium size businesses primarily in the United States, and to other operators globally by acquiring strategic technology assets and existing turnkey VoIP and independent operators. This approach avoids the higher risk and more costly model of relying on exclusively organic growth.
On January 17, 2012 Axiologix acquired substantially all of the assets and liabilities of VOIP ACQ, Inc. that has a number of agreements to make further acquisitions in the VoIP and Cloud Services markets.
On March 5, 2012 Axiologix, through a wholly owned subsidiary in Ireland, Axiologix Limited, acquired substantially all of the assets of Prime Carrier Limited, a Cloud services company serving the international telecoms marketplace that continues to trade under the business name Prime Carrier.
Axiologix is headquartered in Sarasota, FL with International operations in Dublin, Ireland.
Subsidiaries
http://www.axiologix.net/subsidiariesall.html
Axiocomm is a Technology and Services Organization focused on delivering Hosted PBX/VoIP and other cloud based services.
Axiocomm is a wholly owned subsidiary to offer IP voice, data and Cloud services directly to small and medium sized businesses throughout the United States.
To this end AxioComm is partnering with leading technology and service providers to allow us to offer exciting new and competitive services to customers across the United States. AxioComm services are currently being sold via master sales agents that bring a large network of sales resources across the nation.
For further information of Axiocomm's solutions please visit - http://www.axiocomm.net
International Wholesale Carrier Rate & Route Optimization Software
On March 5, 2012 Axiologix completed the acquisition of the assets, business operations and customer contracts of Prime Carrier Ltd., through a wholly owned subsidiary Axiologix Ltd., based in Dublin, Ireland.
Following this acquisition Axiologix Ltd. will continue the business under the registered business name "Prime Carrier".
Prime Carrier is the proven leader in ‘On Demand’ solution to support inter-carrier trading of International Voice traffic. The MOST solution offers an easy-to-use Cloud-based software that can reduce a Telecommunication Carrier's costs by ensuring that the best rates are used in their Traffic Routing.
For further information of Prime Carrier's solutions please visit - http://www.primecarrier.com
Prime Carrier is a registered business name of Axiologix Ltd, Company Number: 443993
Registered Offices: Lis Cara Business Centre, 51-52 Fitzwilliam Square West, Dublin 2, Ireland
Axiologix, Inc. is publicly traded on the OTC Market under the symbol, “AXLX”, and within the OTC-PINK Current Information market tier. As such, Business, Operational, and Financial information on AXLX is available to public view.
Visit: http://www.otcmarkets.com/stock/AXLX/company-info to see complete details.
Axiologix, Inc. is Active on the Nevada Secretary of State site:
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=GxMpei%252bcW5URsoF2m9EV%252fw%253d%253d&nt7=0
A/S: 3 Billion
O/S: 1.2 Billion
FLOAT: 360 Million
(Please note the share structure posted is what we have gathered but can change on a daily basis. Contact the Company or Transfer Agent to get the most current information.)
Their latest 10-Q Quarterly Report:
Filed on 2/20/13 ~ For the period ending 11/30/12
http://www.otcmarkets.com/financialReportViewer?symbol=AXLX&id=99608
Incorporated In: Nevada in 2011
Transfer Agent:
American Stock Transfer & Trust Company
Operations Center
6201 15th Avenue
Brooklyn, NY 11219
Phone: 718-921-8200
News Disclaimer - The following Press Releases have not been investigated by Penny Stock Mobsters, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the links for the following press releases may be from a familiar and reputable company, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. Penny Stock Mobsters will not be held responsible for any news release including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.
PR Newswire - (February 26)
Axiologix Enters Into $800,000 Equity Transaction With Institutional Investor Ironridge Technology Co. - Underpinning Growth And Acquisition Strategy
http://finance.yahoo.com/news/axiologix-enters-800-000-equity-140200370.html
PR Newswire - (February 20)
Axiologix To Acquire Leading Provider Of IP Voice, Data And Managed Services With Revenues Exceeding $6M Per Year
http://finance.yahoo.com/news/axiologix-acquire-leading-provider-ip-123000457.html
PR Newswire - (February 11)
Axiologix subsidiary axiocomm launches new website and online ordering capability for nationwide business phone services
http://finance.yahoo.com/news/axiologix-subsidiary-axiocomm-launches-website-131700080.html
PR Newswire - (January 14)
Axiologix Subsidiary Announces Partnership To Offer IP Voice, Data And Cloud Services Via Nationwide Agent Channel
http://finance.yahoo.com/news/axiologix-subsidiary-announces-partnership-offer-183100429.html
Contact Us:
US Headquarters
Axiologix, Ltd.
1990 Main Street, Suite 750,
Sarasota, FL 34236
Fax: +1 (908) 781 1489
Telephone: +1 (908) 719 8920
International Headquarters
Axiologix, Ltd.
Lis Cara Business Centre
51-52 Fitzwilliam Square West
Dublin 2
Ireland
Fax: +353 (0)1 6650480
Telephone: +353 (0)1 665 0448
This Alert Brought to you by Wall Street Mobsters
Contact Us - admin@pennystockmobsters.com
Newsletter Sign Up - http://trumpia.com/onlineSignup/PSMobsters/Family
Penny Stocks are very volatile and with investing in any security there is always risk.
Always Educate yourself and do your own Due Diligence before investing in ANY Security.
Sources: http://www.bloomberg.com - http://www.finance.yahoo.com - http://www.businessweek.com - http://www.otcmarkets.com/marketActivity/current-otc-market
(these are only sources and not always up to date)
If you are new to trading penny stocks we strongly advise you to spend some time trading virtual money. They say that “You never really become a real trader until you wipeout your portfolio.” We say take that wipeout while not losing your real money.
Here are a few sites where you can easily set up a virtual account:
First check your broker, some have them already like TD Ameritrade/Think or Swim
https://www.tdameritrade.com/tradingtools/compareplatforms.html
Howthemarketworks.com
http://www.howthemarketworks.com
Wallstreetsurvivors.com
http://www.wallstreetsurvivor.com
Mobsters Friday Hit List is $AXLX
AXLX - Axiologix, Inc.
Company Overview
Website - http://www.axiologix.net
Axiologix is an International Technology and Services Organization focused on delivering Cloud-based Products and Services.
Axiologix is creating a nationwide Service Provider of Voice, Data and Cloud services to small and medium size businesses primarily in the United States, and to other operators globally by acquiring strategic technology assets and existing turnkey VoIP and independent operators. This approach avoids the higher risk and more costly model of relying on exclusively organic growth.
On January 17, 2012 Axiologix acquired substantially all of the assets and liabilities of VOIP ACQ, Inc. that has a number of agreements to make further acquisitions in the VoIP and Cloud Services markets.
On March 5, 2012 Axiologix, through a wholly owned subsidiary in Ireland, Axiologix Limited, acquired substantially all of the assets of Prime Carrier Limited, a Cloud services company serving the international telecoms marketplace that continues to trade under the business name Prime Carrier.
Axiologix is headquartered in Sarasota, FL with International operations in Dublin, Ireland.
Subsidiaries
http://www.axiologix.net/subsidiariesall.html
Axiocomm is a Technology and Services Organization focused on delivering Hosted PBX/VoIP and other cloud based services.
Axiocomm is a wholly owned subsidiary to offer IP voice, data and Cloud services directly to small and medium sized businesses throughout the United States.
To this end AxioComm is partnering with leading technology and service providers to allow us to offer exciting new and competitive services to customers across the United States. AxioComm services are currently being sold via master sales agents that bring a large network of sales resources across the nation.
For further information of Axiocomm's solutions please visit - http://www.axiocomm.net
International Wholesale Carrier Rate & Route Optimization Software
On March 5, 2012 Axiologix completed the acquisition of the assets, business operations and customer contracts of Prime Carrier Ltd., through a wholly owned subsidiary Axiologix Ltd., based in Dublin, Ireland.
Following this acquisition Axiologix Ltd. will continue the business under the registered business name "Prime Carrier".
Prime Carrier is the proven leader in ‘On Demand’ solution to support inter-carrier trading of International Voice traffic. The MOST solution offers an easy-to-use Cloud-based software that can reduce a Telecommunication Carrier's costs by ensuring that the best rates are used in their Traffic Routing.
For further information of Prime Carrier's solutions please visit - http://www.primecarrier.com
Prime Carrier is a registered business name of Axiologix Ltd, Company Number: 443993
Registered Offices: Lis Cara Business Centre, 51-52 Fitzwilliam Square West, Dublin 2, Ireland
Axiologix, Inc. is publicly traded on the OTC Market under the symbol, “AXLX”, and within the OTC-PINK Current Information market tier. As such, Business, Operational, and Financial information on AXLX is available to public view.
Visit: http://www.otcmarkets.com/stock/AXLX/company-info to see complete details.
Axiologix, Inc. is Active on the Nevada Secretary of State site:
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=GxMpei%252bcW5URsoF2m9EV%252fw%253d%253d&nt7=0
A/S: 3 Billion
O/S: 1.2 Billion
FLOAT: 360 Million
(Please note the share structure posted is what we have gathered but can change on a daily basis. Contact the Company or Transfer Agent to get the most current information.)
Their latest 10-Q Quarterly Report:
Filed on 2/20/13 ~ For the period ending 11/30/12
http://www.otcmarkets.com/financialReportViewer?symbol=AXLX&id=99608
Incorporated In: Nevada in 2011
Transfer Agent:
American Stock Transfer & Trust Company
Operations Center
6201 15th Avenue
Brooklyn, NY 11219
Phone: 718-921-8200
News Disclaimer - The following Press Releases have not been investigated by Penny Stock Mobsters, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the links for the following press releases may be from a familiar and reputable company, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. Penny Stock Mobsters will not be held responsible for any news release including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.
PR Newswire - (February 26)
Axiologix Enters Into $800,000 Equity Transaction With Institutional Investor Ironridge Technology Co. - Underpinning Growth And Acquisition Strategy
http://finance.yahoo.com/news/axiologix-enters-800-000-equity-140200370.html
PR Newswire - (February 20)
Axiologix To Acquire Leading Provider Of IP Voice, Data And Managed Services With Revenues Exceeding $6M Per Year
http://finance.yahoo.com/news/axiologix-acquire-leading-provider-ip-123000457.html
PR Newswire - (February 11)
Axiologix subsidiary axiocomm launches new website and online ordering capability for nationwide business phone services
http://finance.yahoo.com/news/axiologix-subsidiary-axiocomm-launches-website-131700080.html
PR Newswire - (January 14)
Axiologix Subsidiary Announces Partnership To Offer IP Voice, Data And Cloud Services Via Nationwide Agent Channel
http://finance.yahoo.com/news/axiologix-subsidiary-announces-partnership-offer-183100429.html
Contact Us:
US Headquarters
Axiologix, Ltd.
1990 Main Street, Suite 750,
Sarasota, FL 34236
Fax: +1 (908) 781 1489
Telephone: +1 (908) 719 8920
International Headquarters
Axiologix, Ltd.
Lis Cara Business Centre
51-52 Fitzwilliam Square West
Dublin 2
Ireland
Fax: +353 (0)1 6650480
Telephone: +353 (0)1 665 0448
This Alert Brought to you by Wall Street Mobsters
Contact Us - admin@pennystockmobsters.com
Newsletter Sign Up - http://trumpia.com/onlineSignup/PSMobsters/Family
Penny Stocks are very volatile and with investing in any security there is always risk.
Always Educate yourself and do your own Due Diligence before investing in ANY Security.
Sources: http://www.bloomberg.com - http://www.finance.yahoo.com - http://www.businessweek.com - http://www.otcmarkets.com/marketActivity/current-otc-market
(these are only sources and not always up to date)
If you are new to trading penny stocks we strongly advise you to spend some time trading virtual money. They say that “You never really become a real trader until you wipeout your portfolio.” We say take that wipeout while not losing your real money.
Here are a few sites where you can easily set up a virtual account:
First check your broker, some have them already like TD Ameritrade/Think or Swim
https://www.tdameritrade.com/tradingtools/compareplatforms.html
Howthemarketworks.com
http://www.howthemarketworks.com
Wallstreetsurvivors.com
http://www.wallstreetsurvivor.com
$IMMB big hits coming in now, setting up for EOD
$IMMB big hits coming in now, setting up for EOD
$IMMB big hits coming in now, setting up for EOD
$IMMB .28x.29 HERE WE GOOOOOOO!!!!!!!!!!!
$IMMB .28x.29 HERE WE GOOOOOOO!!!!!!!!!!!
$IMMB .28x.29 HERE WE GOOOOOOO!!!!!!!!!!!
$IMMB bidders stacking, fighting for shares!
$IMMB bidders stacking, fighting for shares!
$IMMB bidders stacking, fighting for shares!
$IMMB 1 piggy left at .295!!
$IMMB 1 piggy left at .295!!
$IMMB 1 piggy left at .295!!
$IMMB + 30% right out of the gate! HUGE DAY COMING!
$IMMB + 30% right out of the gate! HUGE DAY COMING!
$IMMB + 30% right out of the gate! HUGE DAY COMING!
$IMMB HIV-AIDS Treatment NEWS:
http://finance.yahoo.com/news/immunotech-announces-canadian-special-access-141200702.html
$IMMB HIV-AIDS Treatment NEWS:
http://finance.yahoo.com/news/immunotech-announces-canadian-special-access-141200702.html
$IMMB HIV-AIDS Treatment NEWS:
http://finance.yahoo.com/news/immunotech-announces-canadian-special-access-141200702.html
Immunotech Announces Canadian Special Access Program Could Allow Legal Treatment of Company's Patented (IPF-ITV-1) AIDS-HIV Treatment
Press Release: Immunotech Laboratories Inc. – 8 minutes ago
Email
RecommendTweet
Print
RELATED CONTENT
RELATED QUOTES
Symbol Price Change
IMMB 0.213
MONROVIA, CA--(Marketwire - Mar 7, 2013) - Immunotech Laboratories, Inc. ( PINKSHEETS : IMMB ) today announced the company has entered negotiations with a Canadian Wellness Organization for the use of Immunotech's Patented AIDS-HIV Treatment.
Immunotech's Chief Scientific Officer commented, "Canada has a Special Access Program (SAP) for Experimental Drugs for Treatment of Life Threatening and Terminal Diseases, such as Immunotech's IPF-ITV AIDS-HIV Treatment."
The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radiopharmaceutical products and upon satisfactory due diligence and agreement of terms by both parties an agreement such as this could be expedited to implement the legal treatment of the IPF-ITV-1 Treatment in short order, which could result in helping save lives of terminal patients right away. The results from these patients could assist with the Clinical Trials for FDA approval in the United States.
Background on the Special Access Program
The SAP considers requests from practitioners for access to non-marketed drugs for treatment, diagnosis or prevention of serious or life-threatening conditions when conventional therapies have been considered and ruled out, have failed, are unsuitable, and/or unavailable. The regulatory authority supporting the program is discretionary and a decision to authorize or deny a request is made on a case-by-case basis by taking into consideration the nature of the medical emergency, the availability of marketed alternatives and the information provided in support of the request regarding the use, safety and efficacy of the drug. This authority however, does not extend to covering the cost of drugs and does not take into consideration the cost of marketed alternatives. If access is granted, the physician agrees to report on the use of the drug including any adverse events encountered with such use, and must account for all quantities received to both the SAP and the manufacturer.
The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada.
According to the CDC, millions of people worldwide are infected today with HIV/AIDS.
More than 34 million people now live with the HIV/AIDS Virus according to "amfAR" The Foundation for AIDS Research.
Link to SAP Program & Application:
www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index_e.html
RECENT ARTICLES & LINKS FOR RELATIVE AIDS-HIV MEDICINE & BABY HIV CURES
http://timesofindia.indiatimes.com//articleshow/18786108.cms?intenttarget=no
http://www.mccormick.northwestern.edu/news/articles/2012/10/david-kelso-HIV-clinical-trial-in-mozambique.html#.UTTtjmHF-PI.email
http://www.amfar.org/about_hiv_and_aids/facts_and_stats/statistics__worldwide/
About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV and Aids. www.immunotechlab.com
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.
Contact:
Company
Immunotech Laboratories, Inc.
Email Contact
Investor Relations:
The Nabors Group:
713-875-9200
E-mail: Email Contact
www.facebook.com/Naborsgroup
Immunotech Announces Canadian Special Access Program Could Allow Legal Treatment of Company's Patented (IPF-ITV-1) AIDS-HIV Treatment
Press Release: Immunotech Laboratories Inc. – 8 minutes ago
Email
RecommendTweet
Print
RELATED CONTENT
RELATED QUOTES
Symbol Price Change
IMMB 0.213
MONROVIA, CA--(Marketwire - Mar 7, 2013) - Immunotech Laboratories, Inc. ( PINKSHEETS : IMMB ) today announced the company has entered negotiations with a Canadian Wellness Organization for the use of Immunotech's Patented AIDS-HIV Treatment.
Immunotech's Chief Scientific Officer commented, "Canada has a Special Access Program (SAP) for Experimental Drugs for Treatment of Life Threatening and Terminal Diseases, such as Immunotech's IPF-ITV AIDS-HIV Treatment."
The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radiopharmaceutical products and upon satisfactory due diligence and agreement of terms by both parties an agreement such as this could be expedited to implement the legal treatment of the IPF-ITV-1 Treatment in short order, which could result in helping save lives of terminal patients right away. The results from these patients could assist with the Clinical Trials for FDA approval in the United States.
Background on the Special Access Program
The SAP considers requests from practitioners for access to non-marketed drugs for treatment, diagnosis or prevention of serious or life-threatening conditions when conventional therapies have been considered and ruled out, have failed, are unsuitable, and/or unavailable. The regulatory authority supporting the program is discretionary and a decision to authorize or deny a request is made on a case-by-case basis by taking into consideration the nature of the medical emergency, the availability of marketed alternatives and the information provided in support of the request regarding the use, safety and efficacy of the drug. This authority however, does not extend to covering the cost of drugs and does not take into consideration the cost of marketed alternatives. If access is granted, the physician agrees to report on the use of the drug including any adverse events encountered with such use, and must account for all quantities received to both the SAP and the manufacturer.
The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada.
According to the CDC, millions of people worldwide are infected today with HIV/AIDS.
More than 34 million people now live with the HIV/AIDS Virus according to "amfAR" The Foundation for AIDS Research.
Link to SAP Program & Application:
www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index_e.html
RECENT ARTICLES & LINKS FOR RELATIVE AIDS-HIV MEDICINE & BABY HIV CURES
http://timesofindia.indiatimes.com//articleshow/18786108.cms?intenttarget=no
http://www.mccormick.northwestern.edu/news/articles/2012/10/david-kelso-HIV-clinical-trial-in-mozambique.html#.UTTtjmHF-PI.email
http://www.amfar.org/about_hiv_and_aids/facts_and_stats/statistics__worldwide/
About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV and Aids. www.immunotechlab.com
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.
Contact:
Company
Immunotech Laboratories, Inc.
Email Contact
Investor Relations:
The Nabors Group:
713-875-9200
E-mail: Email Contact
www.facebook.com/Naborsgroup
Immunotech Announces Canadian Special Access Program Could Allow Legal Treatment of Company's Patented (IPF-ITV-1) AIDS-HIV Treatment
Press Release: Immunotech Laboratories Inc. – 8 minutes ago
Email
RecommendTweet
Print
RELATED CONTENT
RELATED QUOTES
Symbol Price Change
IMMB 0.213
MONROVIA, CA--(Marketwire - Mar 7, 2013) - Immunotech Laboratories, Inc. ( PINKSHEETS : IMMB ) today announced the company has entered negotiations with a Canadian Wellness Organization for the use of Immunotech's Patented AIDS-HIV Treatment.
Immunotech's Chief Scientific Officer commented, "Canada has a Special Access Program (SAP) for Experimental Drugs for Treatment of Life Threatening and Terminal Diseases, such as Immunotech's IPF-ITV AIDS-HIV Treatment."
The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radiopharmaceutical products and upon satisfactory due diligence and agreement of terms by both parties an agreement such as this could be expedited to implement the legal treatment of the IPF-ITV-1 Treatment in short order, which could result in helping save lives of terminal patients right away. The results from these patients could assist with the Clinical Trials for FDA approval in the United States.
Background on the Special Access Program
The SAP considers requests from practitioners for access to non-marketed drugs for treatment, diagnosis or prevention of serious or life-threatening conditions when conventional therapies have been considered and ruled out, have failed, are unsuitable, and/or unavailable. The regulatory authority supporting the program is discretionary and a decision to authorize or deny a request is made on a case-by-case basis by taking into consideration the nature of the medical emergency, the availability of marketed alternatives and the information provided in support of the request regarding the use, safety and efficacy of the drug. This authority however, does not extend to covering the cost of drugs and does not take into consideration the cost of marketed alternatives. If access is granted, the physician agrees to report on the use of the drug including any adverse events encountered with such use, and must account for all quantities received to both the SAP and the manufacturer.
The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada.
According to the CDC, millions of people worldwide are infected today with HIV/AIDS.
More than 34 million people now live with the HIV/AIDS Virus according to "amfAR" The Foundation for AIDS Research.
Link to SAP Program & Application:
www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index_e.html
RECENT ARTICLES & LINKS FOR RELATIVE AIDS-HIV MEDICINE & BABY HIV CURES
http://timesofindia.indiatimes.com//articleshow/18786108.cms?intenttarget=no
http://www.mccormick.northwestern.edu/news/articles/2012/10/david-kelso-HIV-clinical-trial-in-mozambique.html#.UTTtjmHF-PI.email
http://www.amfar.org/about_hiv_and_aids/facts_and_stats/statistics__worldwide/
About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV and Aids. www.immunotechlab.com
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.
Contact:
Company
Immunotech Laboratories, Inc.
Email Contact
Investor Relations:
The Nabors Group:
713-875-9200
E-mail: Email Contact
www.facebook.com/Naborsgroup
$IMMB ready for TAKEOFF!
$IMMB ready for TAKEOFF!
$IMMB ready for TAKEOFF!
$IMMB- Annotated Video Chart
$IMMB- Annotated Video Chart
$IMMB- Annotated Video Chart